J Korean Ophthalmol Soc.  2008 Aug;49(8):1269-1274. 10.3341/jkos.2008.49.8.1269.

Intravitreal Triamcinolone Injection with or Without Bevacizumab for Diabetic Macular Edema

Affiliations
  • 1Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea. dumky@unitel.co.kr

Abstract

PURPOSE
To compare the effect of intravitreal triamcinolone injection with and without bevacizumab for diabetic macular edema.
METHODS
Of 69 patients (69 eyes) diagnosed with diabetic macular edema without any history of other intraocular disease or intraocular operation, 45 eyes (45 patients) were injected with intravitreal triamcinolone (4 mg) and the remaining eyes (24 patients) were injected with triamcinolone (2 mg) and bevacizumab (1.25 mg). The visual acuity and central macular thickness of treated eyes from both groups was measured using OCT, and these measurements were compared between the two groups.
RESULTS
There were no statistical differences between the two groups with respect to baseline data. Central macular thickness (CMT) was reduced in both groups, and BCVA improved in both groups. No significant differences were detected in changes in CMT or BCVA between the two groups.
CONCLUSIONS
Intravitreal injection of triamcinolone had a beneficial effect on DME in terms of CMT reduction and BCVA improvement. Addition of three consecutive intravitreal bevacizumab injections, however, did not show any significant addictive effect during the follow-up period.

Keyword

BCVA; Bevacizumab; CMT; Triamcinolone

MeSH Terms

Antibodies, Monoclonal, Humanized
Eye
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema
Triamcinolone
Visual Acuity
Bevacizumab
Antibodies, Monoclonal, Humanized
Triamcinolone

Cited by  7 articles

Combined Therapy of Intravitreal Bevacizumab and Posterior Subtenon Triamcinolone Acetonide Injection in Diabetic Macular Edema
Hoon Dong Kim, Kyung Seek Choi, Sung Jin Lee
J Korean Ophthalmol Soc. 2009;50(11):1652-1656.    doi: 10.3341/jkos.2009.50.11.1652.

Electrophysiological and Morphological Changes After Intravitreal Bevacizumab Injection with Macular Edema or Choroidal Neovascularization
Hyun Joon Lee, Joo Youn Park, Young-Hoon Ohn
J Korean Ophthalmol Soc. 2009;50(12):1824-1830.    doi: 10.3341/jkos.2009.50.12.1824.

Intravitreal Bevacizumab Injection as Preoperative Adjuvant of Vitrectomy for Proliferative Diabetic Retinopathy
Min Kyu Shin, Na Mi Kim, Ji Eun Lee, Boo Sup Oum
J Korean Ophthalmol Soc. 2009;50(5):731-737.    doi: 10.3341/jkos.2009.50.5.731.

Comparison of Intravitreal Triamcinolone Versus Bevacizumab in Bilateral Diabetic Macular Edema by Optical Coherence Tomography (OCT) Patterns
Sang Hyun Kim, Jung Min Park
J Korean Ophthalmol Soc. 2010;51(2):210-219.    doi: 10.3341/jkos.2010.51.2.210.

The Effects of Intravitreal Bevacizumab Injection According to the Type of Diabetic Macular Edema
Jae Hoon Jeong, Eung Suk Kim, Jeong Kyu Lee, Nam Ju Moon, Ho Kyun Cho
J Korean Ophthalmol Soc. 2010;51(5):700-706.    doi: 10.3341/jkos.2010.51.5.700.

Treatment of Diabetic Macular Edema: A Comparative Study
Yong Jun Lee, Kyung Seek Choi, Sung Jin Lee
J Korean Ophthalmol Soc. 2010;51(6):849-859.    doi: 10.3341/jkos.2010.51.6.849.

The Long-Term Observation of Intraocular Pressure after Intravitreal Injections of Bevacizumab, Triamcinolone, and Combination of Both
Yong Woon Shin, Hee Yoon Cho, Yoon Jung Lee, Min Chul Seong
J Korean Ophthalmol Soc. 2011;52(5):574-581.    doi: 10.3341/jkos.2011.52.5.574.


Reference

References

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103:1796–806.
2. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987; 94:761–74.
3. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline : ETDRS report no. 19. Arch Ophthalmol. 1995; 113:1144–55.
4. Martidis A, Duker JS, Greenberg PB. . Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920–7.
Article
5. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980; 90:810–6.
Article
6. Aiello LP, Avery RL, Arrigg PG. . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl JMed. 1994; 331:1480–7.
Article
7. Funatsu H, Yamashita H, Ikeda T. . Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003; 110:1690–6.
Article
8. Funatsu H, Yamashita H, Ikeda T. . Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002; 133:537–43.
Article
9. Haritoglou C, Kook D, Neubauer A. . Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999–1005.
Article
10. Audren F, Lecleire-Collet A, Erginay A. . Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.
Article
11. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007; 39:96–110.
Article
12. Massin P, Audren F, Haouchine B. . Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111:218–24.
13. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol Vis Sci. 1977; 16:69–73.
14. Wilson CA, Berkowitz BA, Sato Y. . Treatment with ntravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110:1155–9.
15. Schindler RH, Chandler D, Thresher R, Machmer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93:415–7.
Article
16. Beer PM, Bakri SJ, Singh RJ. . Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110:681–6.
Article
17. Gillies MC, Simpson JM, Billson FA. . Safety of intravitreal injection of triamcinolone. Arch Ophthalmol. 2004; 122:336–40.
18. Strom C, Sander B, Klemp K. . Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci. 2005; 46:3855–8.
19. Arevalo JF. . Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007; 114:743–50.
20. Chun DW, Heier JS, Topping TM. . A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113:1706–12.
Article
21. Ahmadieh H, Ramezani A, Shoeibi N. . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2008; 246:483–9.
22. Paccola L, Costa RA, Folgosa MS. . Intravitreal Triamcinolone versus Bevacizumab for treatment of Refractory Diabetic Macular Edema (IBEME study). Br J Ophthalmol. 2008; 92:76–80.
23. Audren F, Lecleire-Collet A, Erginay A. . Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.
Article
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr